Lee M, Abousaud A, Harkins RA, Marin E, Balasubramani D, Churnetski MC, et al. Important considerations in the diagnosis and management of post-transplant lymphoproliferative disorder. Curr Oncol Rep. 2023;25:883–95. https://doi.org/10.1007/s11912-023-01418-0.

Article  PubMed  CAS  Google Scholar 

Lindsay J, Othman J, Heldman MR, Slavin MA. Epstein-Barr virus posttransplant lymphoproliferative disorder: update on management and outcomes. Curr Opin Infect Dis. 2021;34:635–45. https://doi.org/10.1097/QCO.0000000000000787.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Styczynski J, Einsele H, Gil L, Ljungman P. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis. 2009;11:383–92. https://doi.org/10.1111/j.1399-3062.2009.00411.x.

Article  PubMed  CAS  Google Scholar 

Coppoletta S, Tedone E, Galano B, Soracco M, Raiola AM, Lamparelli T, et al. Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17:901–7. https://doi.org/10.1016/j.bbmt.2010.10.003.

Article  PubMed  CAS  Google Scholar 

Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010;115:925–35. https://doi.org/10.1182/blood-2009-08-239186.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Styczynski J, Reusser P, Einsele H, de la Camara R, Cordonnier C, Ward KN, et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant. 2009;43:757–70. https://doi.org/10.1038/bmt.2008.386.

Article  PubMed  CAS  Google Scholar 

Yan N, Wang N, Zhang P, Wang G, Mao X, Peng D, et al. Case report: successful chimeric antigen receptor T cell therapy in haploidentical-allogeneic stem cell transplant patients with post-transplant lymphoproliferative disorder. Front Oncol. 2021;11:709370. https://doi.org/10.3389/fonc.2021.709370.

Article  PubMed  PubMed Central  Google Scholar 

Luttwak E, Hagin D, Perry C, Wolach O, Itchaki G, Amit O, et al. Anti-CD19 CAR-T therapy for EBV-negative posttransplantation lymphoproliferative disease-a single center case series. Bone Marrow Transplant. 2021;56:1031–7. https://doi.org/10.1038/s41409-020-01145-1.

Chen S, An L, Han J, Zheng X, Zhang X, Li G, et al. Successful Blinatumomab treatment in an allogeneic hematopoietic stem cell transplant recipient with EBV-related post-transplant lymphoproliferative disorder: a case report and literature review. Transpl Immunol. 2023;80:101895. https://doi.org/10.1016/j.trim.2023.101895.

Article  PubMed  CAS  Google Scholar 

Janardan S, Horwitz E, Watkins B, Williams K, Chandrakasan S, Qayed M, et al. Blinatumomab induces complete response in refractory PTLD after hematopoietic cell transplantation. Blood Adv. 2022;6:3058–61. https://doi.org/10.1182/bloodadvances.2021006535.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Cesaro S, Pegoraro A, Tridello G, Calore E, Pillon M, Varotto S, et al. A prospective study on modulation of immunosuppression for Epstein-Barr virus reactivation in pediatric patients who underwent unrelated hematopoietic stem-cell transplantation. Transplantation. 2010;89:1533–40. https://doi.org/10.1097/TP.0b013e3181dd6c0a.

Article  PubMed  CAS  Google Scholar 

Cesaro S, Murrone A, Mengoli C, Pillon M, Biasolo MA, Calore E, et al. The real-time polymerase chain reaction-guided modulation of immunosuppression enables the pre-emptive management of Epstein-Barr virus reactivation after allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2005;128:224–33. https://doi.org/10.1111/j.1365-2141.2004.05287.x.

Article  PubMed  Google Scholar 

Prockop S, Mahadeo M, Beitinfaneh A, Chquet S, Stiff P, Reshef R, et al. Multicenter, open-label, phase 3 study of tabelecleucel for solid organ or allogeneic hematopoietic cell transplant recipients with Epstein–Barr virus-driven post transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE). In: American Society of Hematology Annual Meeting. Atlanta, GA, USA, 2021.

Al Hamed R, Bazarbachi AH, Mohty M. Epstein-Barr virus-related post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of allogeneic stem cell transplantation: a comprehensive review from pathogenesis to forthcoming treatment modalities. Bone Marrow Transplant. 2020;55:25–39. https://doi.org/10.1038/s41409-019-0548-7.

Article  PubMed  CAS  Google Scholar 

Dominietto A, Tedone E, Soracco M, Bruno B, Raiola AM, Van Lint MT, et al. In vivo B-cell depletion with rituximab for alternative donor hemopoietic SCT. Bone Marrow Transplant. 2012;47:101–6. https://doi.org/10.1038/bmt.2011.28.

Article  PubMed  CAS  Google Scholar 

Blaes AH, Cao Q, Wagner JE, Young JA, Weisdorf DJ, Brunstein CG. Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2010;16:287–91. https://doi.org/10.1016/j.bbmt.2009.10.008.

Article  PubMed  CAS  Google Scholar 

Kalra A, Roessner C, Jupp J, Williamson T, Tellier R, Chaudhry A, et al. Risk factors for post-transplant lymphoproliferative disorder after Thymoglobulin-conditioned hematopoietic cell transplantation. Clin Transplant. 2018;32. https://doi.org/10.1111/ctr.13150.

van Esser JW, Niesters HG, van der Holt B, Meijer E, Osterhaus AD, Gratama JW, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood. 2002;99:4364–9.

Article  PubMed  Google Scholar 

Kinzel M, Dowhan M, Kalra A, Williamson TS, Dabas R, Jamani K, et al. Risk factors for the incidence of and the mortality due to post-transplant lymphoproliferative disorder after hematopoietic cell transplantation. Transpl Cell Ther. 2022;28:53.e1–10. https://doi.org/10.1016/j.jtct.2021.09.021.

Article  CAS  Google Scholar 

Van Besien K, Bachier-Rodriguez L, Satlin M, Brown MA, Gergis U, Guarneri D, et al. Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk. Leuk Lymphoma. 2019;60:1693–6. https://doi.org/10.1080/10428194.2018.1543877.

Article  PubMed  CAS  Google Scholar 

Patel C, Pasciolla M, Abramova R, Salerno D, Gomez-Arteaga A, Shore TB, et al. Pre-hematopoietic stem cell transplantation rituximab for Epstein-Barr virus and post-lymphoproliferative disorder prophylaxis in alemtuzumab recipients. Transpl Cell Ther. 2023;29:132.e131–5. https://doi.org/10.1016/j.jtct.2022.10.023.

Article  CAS  Google Scholar 

Kalra A, Roessner C, Jupp J, Williamson T, Tellier R, Chaudhry A, et al. Epstein-Barr virus DNAemia monitoring for the management of post-transplant lymphoproliferative disorder. Cytotherapy. 2018;20:706–14. https://doi.org/10.1016/j.jcyt.2018.02.367.

Juvonen E, Aalto S, Tarkkanen J, Volin L, Hedman K, Ruutu T. Retrospective evaluation of serum Epstein Barr virus DNA levels in 406 allogeneic stem cell transplant patients. Haematologica. 2007;92:819–25.

Article  PubMed  CAS  Google Scholar 

Styczynski J, Gil L, Tridello G, Ljungman P, Donnelly JP, van der Velden W, et al. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Clin Infect Dis. 2013;57:794–802. https://doi.org/10.1093/cid/cit391.

Article  PubMed  CAS  Google Scholar 

Lindsay J, Othman J, Yong MK, Ritchie D, Chee L, Tay K, et al. Dynamics of Epstein-Barr virus on post-transplant lymphoproliferative disorders after antithymocyte globulin-conditioned allogeneic hematopoietic cell transplant. Transpl Infect Dis. 2021;23:e13719. https://doi.org/10.1111/tid.13719.

Article  PubMed  CAS  Google Scholar 

Styczynski J, van der Velden W, Fox CP, Engelhard D, de la Camara R, Cordonnier C, et al. Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. Haematologica. 2016;101:803–11. https://doi.org/10.3324/haematol.2016.144428.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Garcia-Cadenas I, Castillo N, Martino R, Barba P, Esquirol A, Novelli S, et al. Impact of Epstein Barr virus-related complications after high-risk allo-SCT in the era of pre-emptive rituximab. Bone Marrow Transplant. 2015;50:579–84. https://doi.org/10.1038/bmt.2014.298.

Article  PubMed  CAS  Google Scholar 

Pinana JL, Sanz J, Esquirol A, Martino R, Picardi A, Barba P, et al. Umbilical cord blood transplantation in adults with advanced Hodgkin’s disease: high incidence of post-transplant lymphoproliferative disease. Eur J Haematol. 2016;96:128–35. https://doi.org/10.1111/ejh.12557.

Article  PubMed  Google Scholar 

McIver Z, Stephens N, Grim A, Barrett AJ. Rituximab administration within 6 months of T cell-depleted allogeneic SCT is associated with prolonged life-threatening cytopenias. Biol Blood Marrow Transplant. 2010;16:1549–56. https://doi.org/10.1016/j.bbmt.2010.05.004.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kinzel M, Kalra A, Khanolkar RA, Williamson TS, Li N, Khan F, et al. Rituximab toxicity after preemptive or therapeutic administration for post-transplant lymphoproliferative disorder. Transpl Cell Ther. 2023;29:43.e41–8. https://doi.org/10.1016/j.jtct.2022.10.013.

Article  CAS  Google Scholar 

Petropoulou AD, Porcher R, Peffault de Latour R, Xhaard A, Weisdorf D, Ribaud P, et al. Increased infection rate after preemptive rituximab treatment for Epstein-Barr virus reactivation after allogeneic hematopoietic stem-cell transplantation. Transplantation. 2012;94:879–83. https://doi.org/10.1097/TP.0b013e3182664042.

Article  PubMed  CAS  Google Scholar 

Semenova T, Lupo J, Alain S, Perrin-Confort G, Grossi L, Dimier J, et al. Multicenter evaluation of whole-blood Epstein-Barr viral load standardization using the WHO international standard. J Clin Microbiol. 2016;54:1746–50. https://doi.org/10.1128/JCM.03336-15.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Preiksaitis JK, Pang XL, Fox JD, Fenton JM, Caliendo AM, Miller GG, et al. Interlaboratory comparison of Epstein-Barr virus viral load assays. Am J Transplant. 2009;9:269–79. https://doi.org/10.1111/j.1600-6143.2008.02514.x.

Article  PubMed  CAS  Google Scholar